Firebrick Pharma (FRE) Stock Price, News & Analysis

Company Overview

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$18.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Medical Equipment
• Current Symbol: ASX:FRE
• CIK: N/A
• Web: www.firebrickpharma.com
• Phone: 1300 301 874
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$1.18 million
• Net Margins: -59.09%
• Pretax Margin: N/A
• Return on Equity: -87.73%
• Return on Assets: -25.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.19
• Quick Ratio: 18.29

Sales & Book Value

• Annual Sales: A$2.75 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 195,670,000
• Free Float: N/A
• Market Cap: A$18.49 million
• Optionable: Not Optionable
• Beta: 1.68